Kubanda Cryotherapy Secures $1.6 Million in Seed Funding to Revolutionize Pet Care with Minimally Invasive Tumor Treatment

Kubanda Cryotherapy is excited to announce the successful raising of $1,600,000 in our latest funding round, marking a significant milestone in our journey to bring groundbreaking veterinary care to the forefront. As pioneers in the veterinary cryotherapy space, we have developed the first minimally invasive treatment for both benign and malignant masses in pets through our innovative CryoNeedle system. Utilizing focused extreme cold, our technique offers a humane alternative to traditional surgical methods, allowing pets to avoid invasive procedures and enjoy a swift recovery, which gets them back to their beloved playtime faster. After six years of rigorous research and development, and successful clinical trials conducted at the esteemed Johns Hopkins Hospital, we are now prepared to launch our treatment offerings across clinics nationwide. This funding will be pivotal in expanding our reach, enhancing our marketing efforts, and supporting ongoing education for veterinary professionals about the efficacy and safety of our cryotherapy treatments. At Kubanda Cryotherapy, we are passionate about providing human-quality care for man's best friends, and with this capital injection, we can further our mission to revolutionize how we approach tumor treatment in veterinary medicine, ensuring that pets receive the best possible care without the stress of surgical intervention. We are incredibly grateful for the support of our investors who share our vision of healthier, happier pets and are excited for the future as we make waves in the veterinary industry!